Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Bedside blood test may reveal how well heart failure treatment works

NCT ID NCT07762521

Knowledge-focused Sponsor: Mao Chen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This observational study looks at whether changes in a blood marker called NT-proBNP, measured at the bedside, can reflect how well fluid is being removed in patients hospitalized with acute decompensated heart failure. Participants receive standard care, and researchers track NT-proBNP levels and congestion signs during the first days in the hospital. The goal is to see if this marker could serve as a useful indicator of treatment response, potentially guiding more personalized heart failure management in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Serial NT-proBNP measurement (a blood test measuring a heart stress marker)
What this could lead to
If successful, this could show that simple bedside NT-proBNP tests help doctors gauge how well heart failure treatment is working, potentially guiding more personalized care in the future.
What could go wrong
This is a small observational study, so it cannot prove cause and effect. The results may not apply to all heart failure patients, and the test is not yet proven to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of adult patients with acute decompensated heart failure admitted to the cardiac intensive care unit. All participants will receive standard guideline-directed medical treatment. The study will prospectively evaluate the relationship between dynamic changes in NT-proBNP levels and clinical decongestion status during hospitalization.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged ≥18 years. * Patients hospitalized in the cardiac intensive care unit (CCU) with a diagnosis of acute decompensated heart failure (ADHF). * Presence of clinical evidence of congestion at admission, including at least one of the following: * Symptoms or signs of volume overload (e.g., dyspnea, orthopnea, peripheral edema, elevated jugular venous pressure). * Pulmonary congestion based on physical examination or imaging findings. * Other clinically recognized evidence of congestion judged by the treating physician. * Patients receiving standard guideline-directed medical treatment for acute decompensated heart failure, including intravenous diuretic therapy according to clinical practice. * Ability to provide informed consent or availability of a legally authorized representative to provide consent. Exclusion Criteria: * Cardiogenic shock or requirement for immediate mechanical circulatory support. * End-stage kidney disease requiring maintenance dialysis or renal replacement therapy at admission. * Acute conditions requiring urgent intervention that may interfere with study assessments, including acute coronary syndrome requiring immediate revascularization or acute pulmonary embolism. * Clinical conditions in which NT-proBNP interpretation is considered unreliable or inappropriate by the investigator. * Expected survival of less than 72 hours, early transfer from the CCU, or inability to complete the core observation period. * Any other condition considered inappropriate for participation by the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute decompensated heart failure (ADHF) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

congestive heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute decompensated heart failure (ADHF)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.